menu
    • menu
    [{"orgOrder":0,"company":"Mustang Bio","sponsor":"Minaris Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"MB-107","moa":"||IL-2G receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Minaris Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Minaris Regenerative Medicine"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2G receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2G receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2G receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-107","moa":"IL-2G receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2G receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2G receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for MB-107

    Menu

    MB-107

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Mustang Bio

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Mustang Bio

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MB-107

    Therapeutic Area : Genetic Disease

    Study Phase : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentivi...

    Details : MB-107, Mustang’s lentiviral gene therapy for X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease, in newly diagnosed infants under the age of two.

    Product Name : MB-107

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    May 19, 2022

    Lead Product(s) : MB-107

    Therapeutic Area : Genetic Disease

    Highest Development Status : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Mustang Bio

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Mustang Bio

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MB-107,Busulfan

    Therapeutic Area : Genetic Disease

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined...

    Details : All 23 treated patients are alive and 20 patients with follow-up greater than 4 months recovered from pre-existing infections, are off protective isolation and prophylactic antimicrobials, and have normal growth velocity.

    Product Name : MB-107

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    March 05, 2022

    Lead Product(s) : MB-107,Busulfan

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Mustang Bio

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Mustang Bio

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MB-107,Busulfan

    Therapeutic Area : Genetic Disease

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Im...

    Details : FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial. Mustang will proceed with its plans to initiate the pivotal Phase 2 trial in newly diagnosed XSCID patients.

    Product Name : MB-107

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    February 02, 2021

    Lead Product(s) : MB-107,Busulfan

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Mustang Bio

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Mustang Bio

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MB-107,Busulfan

    Therapeutic Area : Genetic Disease

    Study Phase : Phase I/ Phase II

    Sponsor : Minaris Regenerative Medicine

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Mustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Deal for MB-107 L...

    Details : The companies have signed an agreement to enable technology transfer and GMP clinical manufacturing of Mustang’s MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency, also known as bubble boy disease, in...

    Product Name : MB-107

    Product Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    November 23, 2020

    Lead Product(s) : MB-107,Busulfan

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase I/ Phase II

    Sponsor : Minaris Regenerative Medicine

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Mustang Bio

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Mustang Bio

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MB-107,Busulfan

    Therapeutic Area : Genetic Disease

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Mustang Bio Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked Severe Combi...

    Details : U.S. Food and Drug Administration (“FDA”) has granted Rare Pediatric Disease Designation to MB-107, Mustang’s lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease, in...

    Product Name : MB-107

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    August 17, 2020

    Lead Product(s) : MB-107,Busulfan

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Mustang Bio

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Mustang Bio

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MB-107,Busulfan

    Therapeutic Area : Genetic Disease

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Mustang Bio Receives Advanced Therapy Medicinal Product Classification from EMA for MB-107 Lentiviral Gene The...

    Details : European Medicines Agency has granted Advanced Therapy Medicinal Product classification to MB-107, Mustang’s lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency.

    Product Name : MB-107

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    April 20, 2020

    Lead Product(s) : MB-107,Busulfan

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Mustang Bio

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Mustang Bio

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MB-107,Busulfan

    Therapeutic Area : Genetic Disease

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Mustang Bio Announces Orphan Drug Designation for MB-107 to Treat X-linked Severe Combined Immunodeficiency in...

    Details : U.S. FDA has granted Orphan Drug Designation to MB-107, Mustang’s lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency, also known as bubble boy disease, in newly diagnosed infants under the age of two.

    Product Name : MB-107

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    February 09, 2020

    Lead Product(s) : MB-107,Busulfan

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth